Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma
Stephanie C. Pero, Abhinav B. Nagulapally, Linda Mei, Fan Zhang,*, Giselle S. Sholler, David N. Krag, Girja S. Shukla, Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma, Annals of[...]
Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database
Comparison of Event Free Survival EFS) in High-Risk Neuroblastoma (HRNB) patients receiving Eflornithine (DFMO) Maintenance to an external control immunotherapy study database, Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry,[...]
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance. Javier E. Oesterheld, Genevieve Bergendahl, Donald A. Berry, Elizabeth Lorenzi, Thomas Clinch, Jacqueline[...]
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma
Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline M. Kraveka, William Ferguson, Peter[...]
The Cellular Effects of Physiologic Dosing of DFMO in Neuroblastoma Tumorigenesis
Mulama H. David, Divya Gandra1, Kimberly Q. McKinney, David M. Foureau, Kaitlyn Smith, Jason Haw, Giselle Saulnier Sholler, The Cellular Effects of Physiologic Dosing of DFMO in Neuroblastoma Tumorigenesis, 2022, ASPHO Annual[...]
Utilizing transcriptome analysis to identify targeted therapy for Ewing sarcoma
Smith, K, Gandra, D, McKinney, K, Dykema, K, Nagulapally, A, Mulama, D, Sholler, GS, Oesterheld, J, Trovillion, E. Utilizing transcriptome analysis to identify targeted therapy for Ewing sarcoma. (2022), ASPHO Annual Meeting,[...]
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma
Jacqueline M. Kraveka, Elizabeth C. Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld, Elizabeth Kim, Abhinav B. Nagulapally, Karl J. Dykema, Valerie I. Brown, William D. Roberts, Deanna Mitchell,on E Dslin,[...]
Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma
Maximillian S Westphal 1, Eunjee Lee 1 2, Eric E Schadt 1 2, Giselle S Sholler 3 4, Jun Zhu, Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH[...]
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
Sara A. Byron*, William P. D. Hendricks*, Abhinav B. Nagulapally*, Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E. Eslin, Deanna Mitchell, Albert Cornelius, William Roberts, Michael S.[...]
Genomic Analysis and Precision Therapy for Recurrent and Resistant Sarcoma
Javier Oesterheld, Abhinav B Nagulapally, Karl Dykema, William Ferguson, Michael Isakoff, Erin Trovillion, Genevieve Bergendahl, Giselle Saulnier Sholler, Genomic Analysis and Precision Therapy for Recurrent and Resistant Sarcoma, ASPHO Annual Meeting,[...]